Home Cart Sign in  
Chemical Structure| 173903-47-4 Chemical Structure| 173903-47-4

Structure of Tizoxanide
CAS No.: 173903-47-4

Chemical Structure| 173903-47-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tizoxanide is the main active metabolite of nitazoxanide. Nitazoxanide and tizoxanide have a broad-spectrum anti-infective effect, including parasites, bacteria, and virus.

Synonyms: TIZ; NSC 697856; Desacetyl-nitazoxanide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tizoxanide

CAS No. :173903-47-4
Formula : C10H7N3O4S
M.W : 265.25
SMILES Code : O=C(NC1=NC=C([N+]([O-])=O)S1)C2=CC=CC=C2O
Synonyms :
TIZ; NSC 697856; Desacetyl-nitazoxanide
MDL No. :MFCD07484970
InChI Key :FDTZUTSGGSRHQF-UHFFFAOYSA-N
Pubchem ID :394397

Safety of Tizoxanide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
PC3 cells 20 µM 16 hours Inhibited SKP2 expression, leading to G1 cell cycle arrest Cell Rep Med. 2025 Jan 21;6(1):101890
22Rv1 cells 20 µM 48 hours Induced apoptosis Cell Rep Med. 2025 Jan 21;6(1):101890
DU145 cells 20 µM 16 hours Inhibited cell growth Cell Rep Med. 2025 Jan 21;6(1):101890
C4-2 cells 20 µM 16 hours Inhibited E2F1-mediated gene expression, including genes involved in cell cycle progression, DNA synthesis, and lipid synthesis Cell Rep Med. 2025 Jan 21;6(1):101890
HepG2 cells 1, 5, 10, 25 µM 24 hours Induced mild mitochondrial uncoupling and activated AMPK Acta Pharm Sin B. 2022 Mar;12(3):1322-1338
U87MG cells 1 and 10 µM 24 hours TIZ significantly inhibited the phosphorylation levels of CDK1 Thr161 Front Pharmacol. 2022 May 25;13:895573
Rat chondrocytes 0.5 µM 24 hours To evaluate the effect of Tiz on IL-1β-induced inflammatory response and cartilage matrix degradation, results showed that Tiz could alleviate IL-1β-induced inflammatory response and cartilage matrix degradation. Heliyon. 2023 Aug 26;9(9):e19472
Rat chondrocytes 0.125, 0.25, 0.5 µM 24 hours To evaluate the effect of Tiz on chondrocyte viability, results showed that Tiz at 0.125, 0.25 and 0.5 μM had no toxic effects on cells. Heliyon. 2023 Aug 26;9(9):e19472
Vero cells 0.5 μg/mL 24 hours To study the effect of TIZ on the proteome of Vero cells, identifying 15 differentially expressed proteins involved in various biological processes including translation, intracellular trafficking, RNA processing and modification, and signal transduction. Sci Rep. 2020 Sep 7;10(1):14733
A172 cells 0.01 to 10 µM 24, 48, and 72 hours TIZ dose-dependently inhibited cell proliferation with an IC50 of 0.73 µM at 48 h Front Pharmacol. 2022 May 25;13:895573
U118MG cells 0.01 to 10 µM 24, 48, and 72 hours TIZ dose-dependently inhibited cell proliferation with an IC50 of 2.31 µM at 48 h Front Pharmacol. 2022 May 25;13:895573
U87MG cells 0.01 to 10 µM 24, 48, and 72 hours TIZ dose-dependently inhibited cell proliferation with an IC50 of 1.10 µM at 48 h Front Pharmacol. 2022 May 25;13:895573
MCF-7 cells 30 µM 3 hours or 24 hours Induced autophagosome formation, assessed by increased punctate EGFP-LC3 fluorescence and increased EGFP-LC3II lipidation product PLoS Pathog. 2012;8(5):e1002691
Marc-145-GFP cells 5 µM 36 hours Evaluate the inhibitory effect of Tizoxanide on PRRSV proliferation, results showed Tizoxanide significantly inhibited PRRSV proliferation at 5 μM Nat Commun. 2024 Jun 6;15(1):4813.
Vero E6 cells 3.19 µM 48 hours Evaluate the antiviral activity of Tizoxanide against SARS-CoV-2, showing an EC50 of 7.48 µM EBioMedicine. 2022 Aug;82:104148
Fusobacterium nucleatum 0.06–0.5 μg/ml 48 hours To determine the minimum inhibitory concentration (MIC) of Tizoxanide against Fusobacterium nucleatum, showing an MIC range of 0.06–0.5 μg/ml. Antimicrob Agents Chemother. 2006 Mar;50(3):1112-7
Clostridium difficile 0.015–0.5 μg/ml 48 hours To determine the minimum inhibitory concentration (MIC) of Tizoxanide against Clostridium difficile, showing an MIC range of 0.015–0.5 μg/ml. Antimicrob Agents Chemother. 2006 Mar;50(3):1112-7
Bacteroides fragilis 1.0–4.0 μg/ml 48 hours To determine the minimum inhibitory concentration (MIC) of Tizoxanide against Bacteroides fragilis, showing an MIC range of 1.0–4.0 μg/ml. Antimicrob Agents Chemother. 2006 Mar;50(3):1112-7
Giardia lamblia WB Clone C6 2.6 µM 5 days Evaluate the inhibitory effect of Tizoxanide on the proliferation of Giardia lamblia WB Clone C6, with an IC50 of 2.6 μM. Antimicrob Agents Chemother. 2006 Jan;50(1):162-70
Vero cells 0.5–2.2 µM 72 hours To evaluate the inhibitory effect of Tizoxanide on DENV-2 replication, results showed TIZ could inhibit virus replication with IC50 of 1.38 μM and IC90 of 4.8 μM Viruses. 2023 Mar 7;15(3):696

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Male SD rats OA model induced by anterior cruciate ligament resection and partial medial meniscus removal Intra-articular injection 0.5 μM Once a week for 8 weeks To evaluate the effect of Tiz on cartilage damage in rat OA model, results showed that intra-articular injection of Tiz could significantly alleviate the progression of cartilage damage. Heliyon. 2023 Aug 26;9(9):e19472
Caenorhabditis elegans Wild-type N2 strain and various mutants (e.g., aak-2, daf-16, sir-2.1, rsks-1, akt-1, akt-2) Administered via OP50 E. coli diet 10, 100, 500 μM and 1 mM Continuous treatment for 12 days starting from L4 stage or lifelong treatment Tizoxanide extends lifespan and healthspan in C. elegans, improves high glucose-induced lifespan shortening via Akt/AMPK/sir-2.1/daf-16 pathway, enhances motility, reduces lipofuscin accumulation, improves mitochondrial morphology and function, and activates AMPK-dependent autophagy. Acta Pharm Sin B. 2024 Jul;14(7):3266-3280
BALB/C nude mice Subcutaneous and intracranial orthotopic xenograft models Intraperitoneal injection 5 and 15 mg/kg Three times per week for 3 weeks TIZ significantly suppressed the growth of GBM, prolonged the survival of nude mice without obvious side effects Front Pharmacol. 2022 May 25;13:895573

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02684240 Tuberculosis Phase 2 Completed - Haiti ... More >> Les Centres GHESKIO Port-au-Prince, Haiti Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.77mL

0.75mL

0.38mL

18.85mL

3.77mL

1.89mL

37.70mL

7.54mL

3.77mL

References

 

Historical Records

Categories